Combined treatment of somatostatin analogues with pegvisomant in acromegaly

被引：23

作者：

Franck, S. E. ^{[1
]}

Muhammad, A. ^{[1
]}

van der Lely, A. J. ^{[1
]}

Neggers, S. J. C. M. M. ^{[1
]}

机构：

[1] Erasmus Univ, Med Ctr, Pituitary Ctr Rotterdam, Dept Internal Med,Endocrinol Sect, POB 2040, NL-3000 CA Rotterdam, Netherlands

来源：

ENDOCRINE | 2016年 / 52卷 / 02期

关键词：

Acromegaly; Somatostatin analogues; Growth hormone receptor antagonist; Pegvisomant; Growth hormone; Insulin-like growth factor I; HORMONE-RECEPTOR ANTAGONIST; LONG-TERM TREATMENT; QUALITY-OF-LIFE; INSULIN SENSITIVITY; GALLSTONE FORMATION; LANREOTIDE AUTOGEL; ACTING OCTREOTIDE; CLINICAL-PRACTICE; MEDICAL-TREATMENT; TUMOR SHRINKAGE;

D O I：

10.1007/s12020-015-0810-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of acromegaly with monotherapy long-acting somatostatin analogues (LA-SSA) as primary treatment or after neurosurgery can only achieve complete normalization of insulin-like growth factor I (IGF-I) in roughly 40 % of patients. Recently, one of the acromegaly consensus groups has recommended switching to combined treatment of LA-SSA and pegvisomant (PEGV) in patients with partial response to LA-SSAs. This combination of LA-SSA and PEGV, a growth hormone receptor antagonist, can normalize IGF-I levels in virtually all patients, requiring that the adequate dose of PEGV is used. The required PEGV dose varies significantly between individual acromegaly patients. One of the advantages of the combination therapy is that tumor size control or even tumor shrinkage can be observed in a vast majority of patients. The main side effects of the combination treatment are gastrointestinal symptoms, lipohypertrophy and transient elevated liver transaminases. In this review we provide an overview of the efficacy and safety of the combined treatment of LA-SSAs with PEGV.

引用

页码：206 / 213

页数：8

共 57 条

[1] Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly [J].

Amato, G ;

Mazziotti, G ;

Rotondi, M ;

Iorio, S ;

Doga, M ;

Sorvillo, F ;

Manganella, G ;

Di Salle, F ;

Giustina, A ;

Carella, C .

CLINICAL ENDOCRINOLOGY, 2002, 56 (01) :65-71

[2] A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy [J].

Annamalai, Anand K. ;

Webb, Alison ;

Kandasamy, Narayanan ;

Elkhawad, Maysoon ;

Moir, Samantha ;

Khan, Fakhar ;

Maki-Petaja, Kaisa ;

Gayton, Emma L. ;

Strey, Christopher H. ;

O'Toole, Samuel ;

Ariyaratnam, Shaumya ;

Halsall, David J. ;

Chaudhry, Afzal N. ;

Berman, Laurence ;

Scoffings, Daniel J. ;

Antoun, Nagui M. ;

Dutka, David P. ;

Wilkinson, Ian B. ;

Shneerson, John M. ;

Pickard, John D. ;

Simpson, Helen L. ;

Gurnell, Mark .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (03) :1040-1050

[3] Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].

Barkan, AL ;

Burman, P ;

Clemmons, DR ;

Drake, WM ;

Gagel, RF ;

Harris, PE ;

Trainer, PJ ;

van der Lely, AJ ;

Vance, ML .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691

[4] Wide variation in surgical outcomes for acromegaly in the UK [J].

Bates, P. R. ;

Carson, M. N. ;

Trainer, P. J. ;

Wass, J. A. H. .

CLINICAL ENDOCRINOLOGY, 2008, 68 (01) :136-142

[5] Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome [J].

Bernabeu, Ignacio ;

Marazuela, Monica ;

Lucas, Tomas ;

Loidi, Lourdes ;

Alvarez-Escola, Cristina ;

Luque-Ramirez, Manuel ;

Fernandez-Rodriguez, Eva ;

Paniagua, Amalia-Elisa ;

Quinteiro, Celsa ;

Casanueva, Felipe F. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) :2147-2154

[6] Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes [J].

Bianchi, Antonio ;

Valentini, Ferdinando ;

Iuorio, Raffaella ;

Poggi, Maurizio ;

Baldelli, Roberto ;

Passeri, Marina ;

Giampietro, Antonella ;

Tartaglione, Linda ;

Chiloiro, Sabrina ;

Appetecchia, Marialuisa ;

Gargiulo, Patrizia ;

Fabbri, Andrea ;

Toscano, Vincenzo ;

Pontecorvi, Alfredo ;

De Marinis, Laura .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32

[7] Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis [J].

Biering, H ;

Saller, B ;

Bauditz, J ;

Pirlich, M ;

Rudolph, B ;

Johne, A ;

Buchfelder, M ;

Mann, K ;

Droste, M ;

Schreiber, T ;

Lochs, H ;

Strasburger, CJ .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (02) :213-220

[8] Lipodystrophy in patients with acromegaly receiving pegvisomant [J].

Bonert, Vivien S. ;

Kennedy, Laurence ;

Petersenn, Stephan ;

Barkan, Ariel ;

Carmichael, John ;

Melmed, Shlomo .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (09) :3515-3518

[9] Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study [J].

Buchfelder, M. ;

Weigel, D. ;

Droste, M. ;

Mann, K. ;

Saller, B. ;

Bruebach, K. ;

Stalla, G. K. ;

Bidlingmaier, M. ;

Strasburger, C. J. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (01) :27-35

[10] The German ACROSTUDY: past and present [J].

Buchfelder, M. ;

Schlaffer, S. ;

Droste, M. ;

Mann, K. ;

Saller, B. ;

Bruebach, K. ;

Stalla, G. K. ;

Strasburger, C. J. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 :S3-S10

← 1 2 3 4 5 6 →